European Journal of Internal Medicine
Volume 20, Issue 3 , Pages 236-241 , May 2009

Systemic lupus erythematosus and vaccination

Received 13 April 2008 ,Revised 25 June 2008 ,Accepted 7 July 2008.

References 

  1. Nemazee D. Receptor selection in B and T lymphocytes. Annu Rev Immunol. 2000;18:19–51
  2. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347:911–920
  3. Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence?. Lancet. 2003;362:1659–1666
  4. Tishler M, Shoenfeld Y. Vaccines and autoimmunity. In:  Rose NR,  Mackay IR editor. The autoimmune disease. Fourth ed.. Elsevier; 2006;p. 309–316
  5. Wucherpfennig KW. Mechanisms of the induction of autoimmunity by infectious agents. J Clin Invest. 2001;108:1097–1104
  6. Ang CW, Jacobs BC, Laman JD. The Guillain–Barré syndrome: a true case of molecular mimicry. Trends Immunol. 2004;25:61–66
  7. Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of autoantibodies to beta 2-glycoprotein I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest. 2002;109:797–804
  8. Hemmer B, Jacobsen M, Sommer N. Degeneracy in T-cell antigen recognition: implication for the pathogenesis of autoimmune disease. Neuroimmunology. 2000;107:148–153
  9. Fourneau JM, Bach JM, van Endert PM, Bach JF. The elusive case for a role of mimicry in autoimmune diseases. Mol Immunol. 2004;40:1095–1102
  10. Panoutsakopoulou V, Sanchirico ME, Huster KM, Jansson M, Granucci F, Shim DJ, et al. Analysis of the relationship between viral infection and autoimmune disease. Immunity. 2001;15:137–147
  11. Iriya SM, Capelozzi VL, Calich I, Martins MA, Lichtenstein A. Causes of death in patients with systemic lupus erythematosus in Sao Paulo, Brazil: a study of 113 autopsies. Arch Intern Med. 2001;161:1557–1561
  12. Noel V, Lortholary O, Casassus P, Cohen P, Généreau T, André MH, et al. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis. 2001;60:1141–1144
  13. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine. 1999;78:167–175
  14. Alarcon GS. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, polymyositis/dermatomyositis. Infect Dis Clin North Am. 2006;20:849–875
  15. Ross SC, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine. 1984;63:243–273
  16. Garred P, Voss A, Madsen HO, Junker P. Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum. 1999;42:2145–2152
  17. Mitchell SR, Nguyen PQ, Katz P. Increased risk of neisserial infections in systemic lupus erythematosus. Semin Arthritis Rheum. 1990;20:174–184
  18. Petri M, Genovese M. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus. A prospective study of the Hopkins lupus cohort. J Rheumatol. 1992;19:1559–1565
  19. Hsieh SC, Tsai CY, Sun KH, Yu HS, Tsai ST, Wang JC, et al. Decreased spontaneous and lipopolysaccharide stimulated production of interleukin 8 by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus. Clin Exp Rheumatol. 1994;12:627–633
  20. Boros P, Muryoi T, Spiera H, Bona C, Unkeless JC. Autoantibodies directed against different classes of Fc gamma R are found in sera of autoimmune patients. J Immunol. 1993;150:2018–2024
  21. Bermas BL, Petri M, Goldman D, Mittleman B, Miller MW, Stocks NI, et al. T helper cell dysfunction in systemic lupus erythematosus (SLE). Relation to disease activity. J Clin Immunol. 1994;14:169–177
  22. Cunha BA. Infections in nonleukopenic compromised hosts (diabetes mellitus, SLE, steroids, and asplenia) in critical care. Crit Care Clin. 1998;14:264–282
  23. Duffy KN, Duffy CM, Gladman DD. Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol. 1991;18:1180–1184
  24. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270:286–290
  25. Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum. 1996;39:1475–1482
  26. Kahl LE. Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome. J Rheumatol. 1994;21:84–86
  27. Fox RA. Disseminated lupus erythematosus: an allergic disease?. Arch Pathol. 1943;36:311–315
  28. Ayvazien LF, Badger TL. Disseminated lupus erythematosus occurring among student nurses. N Engl J Med. 1948;239:565–570
  29. Tudela P, Marti S, Bonal J. Systemic lupus erythematosus and vaccination against hepatitis B. Nephron. 1992;62:236
  30. Maillefert JF, Tavernier C, Sibilia J, Vignon E. Exacerbation of systemic lupus erythematosus after hepatitis B vaccination: comment on the article by Battafarano et al. and the letter by Senécal et al.. Arthritis Rheum. 2000;43:468–469
  31. Older SA, Battafarano DF, Enzenauer RJ, Krieg AM. Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature. Semin Arthritis Rheum. 1999;29:131–139
  32. Naveau C, Houssiau FA. Pneumoccocal sepsis in patients with systemic lupus erythematosus. Lupus. 2005;14:903–906
  33. Battafarano DF, Battafarano NJ, Larsen L, Dyer PD, Older SA, Muehlbauer S, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998;41:1828–1834
  34. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis. 2002;34:147–153
  35. Elkayam O, Paran D, Burke M, Zakut V, Ben-Yitshak R, Litinsky I, et al. Pneumococcal vaccination of patients with systemic lupus erythematosus. Effects on generation of autoantibodies. Autoimmunity. 2005;38:493–496
  36. Tarján P, Sipka S, Maródi L, Nemes E, Lakos G, Gyimesi E, et al. No short-term immunological effects of pneumococcus vaccination in patients with systemic lupus erythematosus. Scand J Rheumatol. 2002;31:211–215
  37. MacDonald E, Jarrett MP, Schiffman G, Grayzel AI. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J Rheumatol. 1984;11:306–308
  38. Elkayam O, Ablin J, Caspi D. Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Autoimmun Rev. 2007;6:312–314
  39. O'Neill SG, Isenberg DA. Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety. Lupus. 2006;15:778–783
  40. Whitney CG, Schaffner W, Butler JC. Rethinking recommendations for use of pneumococcal vaccines in adults. Clin Infect Dis. 2001;33:662–675
  41. Temine L, Dab W. [Pneumococcal vaccination : expected benefits in adults]. Rev Med Interne. 2007;28:9–15French
  42. Brown MA, Bertouch JV. Rheumatic complications of influenza vaccination. Aust N Z J Med. 1994;24:572–573
  43. Del Porto F, Laganà B, Biselli R, Donatelli I, Campitelli L, Nisini R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine. 2006;24:3217–3223
  44. Holvast A, Huckriede A, Wilschut J, Horst G, De Vries JJ, Benne CA, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis. 2006;65:913–918
  45. Kuruma KA, Borda EF, Lopes MH, de Carvalho JF, Bonfá E. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus. 2007;16:350–354
  46. Choffray A, Pinquier L, Bachelez H. Exacerbation of lupus panniculitis following anti-hepatitis-B vaccination. Dermatology. 2007;215:152–154
  47. Geier DA, Geier MR. A case–control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity. 2005;38:295–301
  48. Geier MR, Geier DA. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review. Clin Exp Rheumatol. 2004;22:749–755
  49. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Risk factors for development of systemic lupus erythematosus: allergies, infections and family history. J Clin Epidemiol. 2002;55:982–989
  50. Aron-Maor A, Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus. 2001;10:237–240
  51. British Society of Rheumatology (BSR) . Vaccination in the immunocompromised person : guidelines for the patient taking immunosuppressants, steroids and the new biologic therapies. BSR; 2002;http://www.rheumatology.org.uk/guidelines/clinicalguidelines

PII: S0953-6205(08)00215-X

doi: 10.1016/j.ejim.2008.07.017

European Journal of Internal Medicine
Volume 20, Issue 3 , Pages 236-241 , May 2009

Article Tools